

Data Sheet

WWW. UREIKO-CHEM. COM

Global Supplier of Chemical Probes, Inhibitors & Agonists

Product Name :Werner syndrome RecQ helicase-IN-3

Molecular Weight :687.07

Target : Solubility :

Biological Activity

Werner syndrome RecQ helicase-IN-3 (WRN-IN-3) is a small-molecule inhibitor that has been developed as a potential therapeutic for Werner syndrome. WRN-IN-3 works by selectively targeting the ATPase activity of WRN helicase, thereby inhibiting its DNA repair function and inducing apoptosis in cells that are deficient in WRN. Werner syndrome is a rare genetic disorder that affects multiple systems in the body, including the skin, bones, and nervous system. It is caused by mutations in the WRN gene, which encodes a RecQ helicase that plays a key role in DNA repair and maintenance. Individuals with Werner syndrome have a significantly increased risk of developing early onset age-related diseases, such as cancer, cardiovascular disease, and osteoporosis.

References

- 1. Halevy T, Akov S, Bohbot-Raviv Y, et al. Small molecule inhibitors of the werner syndrome recQ helicase exhibit genotoxicity in human cells. J Med Chem. 2012;55(16):7233-7243.
- 2. Lengauer C, Kinzler KW, Vogelstein B. Genetic instabilities in human cancers. Nature. 1998;396(6712):643-649.
- 3. Croteau DL, Popuri V, Opresko PL, et al. WRN suppresses the formation of large deletions from small deletions or non-homologous end joining. DNA Repair (Amst). 2013;12(9):618-628.
- 4. Chen Q, Van der Sluis PC, Navarro S, et al. Small molecule inhibitors and probes for werner syndrome recQ helicase. Mol Biosyst. 2013;9(3):311-317.

Note: All products of Ureiko are only used for scientific research or drug certificate declaration, we do not provide products and services for any personal use!

Caution: Product has not been fully validated for medical applications. Lab Use Only! JACK@UREIKO-CHEM. COM